Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia
© 2022. Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia.
METHODS: We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero.
RESULTS: We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference - 4.3%; 99% confidence interval (CI) - 11.7-3.0; relative risk 0.89; 0.72-1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI - 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (- 3 to 10; P = 0.22).
CONCLUSION: Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
---|---|
Enthalten in: |
Intensive care medicine - 48(2022), 5 vom: 31. Mai, Seite 580-589 |
Sprache: |
Englisch |
---|
Links: |
---|
Themen: |
7S5I7G3JQL |
---|
Anmerkungen: |
Date Completed 02.05.2022 Date Revised 07.12.2022 published: Print-Electronic ClinicalTrials.gov: NCT04509973 Citation Status MEDLINE |
---|
doi: |
10.1007/s00134-022-06677-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM338891668 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM338891668 | ||
003 | DE-627 | ||
005 | 20231226001704.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00134-022-06677-2 |2 doi | |
028 | 5 | 2 | |a pubmed24n1129.xml |
035 | |a (DE-627)NLM338891668 | ||
035 | |a (NLM)35359168 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Granholm, Anders |e verfasserin |4 aut | |
245 | 1 | 0 | |a Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 02.05.2022 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a ClinicalTrials.gov: NCT04509973 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022. Springer-Verlag GmbH Germany, part of Springer Nature. | ||
520 | |a PURPOSE: We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia | ||
520 | |a METHODS: We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero | ||
520 | |a RESULTS: We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference - 4.3%; 99% confidence interval (CI) - 11.7-3.0; relative risk 0.89; 0.72-1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI - 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (- 3 to 10; P = 0.22) | ||
520 | |a CONCLUSION: Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Corticosteroids | |
650 | 4 | |a Critical illness | |
650 | 4 | |a Hypoxaemia | |
650 | 4 | |a Mortality | |
650 | 4 | |a Quality of life | |
650 | 7 | |a Dexamethasone |2 NLM | |
650 | 7 | |a 7S5I7G3JQL |2 NLM | |
700 | 1 | |a Kjær, Maj-Brit Nørregaard |e verfasserin |4 aut | |
700 | 1 | |a Munch, Marie Warrer |e verfasserin |4 aut | |
700 | 1 | |a Myatra, Sheila Nainan |e verfasserin |4 aut | |
700 | 1 | |a Vijayaraghavan, Bharath Kumar Tirupakuzhi |e verfasserin |4 aut | |
700 | 1 | |a Cronhjort, Maria |e verfasserin |4 aut | |
700 | 1 | |a Wahlin, Rebecka Rubenson |e verfasserin |4 aut | |
700 | 1 | |a Jakob, Stephan M |e verfasserin |4 aut | |
700 | 1 | |a Cioccari, Luca |e verfasserin |4 aut | |
700 | 1 | |a Vesterlund, Gitte Kingo |e verfasserin |4 aut | |
700 | 1 | |a Meyhoff, Tine Sylvest |e verfasserin |4 aut | |
700 | 1 | |a Helleberg, Marie |e verfasserin |4 aut | |
700 | 1 | |a Møller, Morten Hylander |e verfasserin |4 aut | |
700 | 1 | |a Benfield, Thomas |e verfasserin |4 aut | |
700 | 1 | |a Venkatesh, Balasubramanian |e verfasserin |4 aut | |
700 | 1 | |a Hammond, Naomi E |e verfasserin |4 aut | |
700 | 1 | |a Micallef, Sharon |e verfasserin |4 aut | |
700 | 1 | |a Bassi, Abhinav |e verfasserin |4 aut | |
700 | 1 | |a John, Oommen |e verfasserin |4 aut | |
700 | 1 | |a Jha, Vivekanand |e verfasserin |4 aut | |
700 | 1 | |a Kristiansen, Klaus Tjelle |e verfasserin |4 aut | |
700 | 1 | |a Ulrik, Charlotte Suppli |e verfasserin |4 aut | |
700 | 1 | |a Jørgensen, Vibeke Lind |e verfasserin |4 aut | |
700 | 1 | |a Smitt, Margit |e verfasserin |4 aut | |
700 | 1 | |a Bestle, Morten H |e verfasserin |4 aut | |
700 | 1 | |a Andreasen, Anne Sofie |e verfasserin |4 aut | |
700 | 1 | |a Poulsen, Lone Musaeus |e verfasserin |4 aut | |
700 | 1 | |a Rasmussen, Bodil Steen |e verfasserin |4 aut | |
700 | 1 | |a Brøchner, Anne Craveiro |e verfasserin |4 aut | |
700 | 1 | |a Strøm, Thomas |e verfasserin |4 aut | |
700 | 1 | |a Møller, Anders |e verfasserin |4 aut | |
700 | 1 | |a Khan, Mohd Saif |e verfasserin |4 aut | |
700 | 1 | |a Padmanaban, Ajay |e verfasserin |4 aut | |
700 | 1 | |a Divatia, Jigeeshu Vasishtha |e verfasserin |4 aut | |
700 | 1 | |a Saseedharan, Sanjith |e verfasserin |4 aut | |
700 | 1 | |a Borawake, Kapil |e verfasserin |4 aut | |
700 | 1 | |a Kapadia, Farhad |e verfasserin |4 aut | |
700 | 1 | |a Dixit, Subhal |e verfasserin |4 aut | |
700 | 1 | |a Chawla, Rajesh |e verfasserin |4 aut | |
700 | 1 | |a Shukla, Urvi |e verfasserin |4 aut | |
700 | 1 | |a Amin, Pravin |e verfasserin |4 aut | |
700 | 1 | |a Chew, Michelle S |e verfasserin |4 aut | |
700 | 1 | |a Wamberg, Christian Aage |e verfasserin |4 aut | |
700 | 1 | |a Bose, Neeta |e verfasserin |4 aut | |
700 | 1 | |a Shah, Mehul S |e verfasserin |4 aut | |
700 | 1 | |a Darfelt, Iben S |e verfasserin |4 aut | |
700 | 1 | |a Gluud, Christian |e verfasserin |4 aut | |
700 | 1 | |a Lange, Theis |e verfasserin |4 aut | |
700 | 1 | |a Perner, Anders |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Intensive care medicine |d 1993 |g 48(2022), 5 vom: 31. Mai, Seite 580-589 |w (DE-627)NLM000234818 |x 1432-1238 |7 nnns |
773 | 1 | 8 | |g volume:48 |g year:2022 |g number:5 |g day:31 |g month:05 |g pages:580-589 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00134-022-06677-2 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 48 |j 2022 |e 5 |b 31 |c 05 |h 580-589 |